Industry News
Pharmaceutical Industry News
Gilead presses HIV drug fraud in court, wins freeze of ‘kingpin’ assets
Gilead presses HIV drug fraud in court, wins freeze of 'kingpin' assets zbecker Tue, 04/19/2022 - 14:33
Novavax, fashionably late to the COVID-19 vaccine party, could still reap $5B in 2022: analyst
Novavax, fashionably late to the COVID-19 vaccine party, could still reap $5B in 2022: analyst fkansteiner Tue, 04/19/2022 - 13:00
Gilead targets 400 jobs, assembles cell therapy manufacturing troika with FDA nod for Maryland site
Gilead targets 400 jobs, assembles cell therapy manufacturing troika with FDA nod for Maryland site aliu Tue, 04/19/2022 - 10:08
Johnson & Johnson, after weak quarter of vaccine sales, will no longer include it in guidance
Johnson & Johnson, after weak quarter of vaccine sales, will no longer include it in guidance kdunleavy Tue, 04/19/2022 - 10:03
SK advances Gates-backed COVID-19 antiviral spray toward clinic
SK advances Gates-backed COVID-19 antiviral spray toward clinic ntaylor Tue, 04/19/2022 - 09:31
Aquestive’s oral rival to EpiPen clears test on path to pivotal trial
Aquestive's oral rival to EpiPen clears test on path to pivotal trial ntaylor Tue, 04/19/2022 - 09:27
Pfizer’s COVID-19 antiviral Paxlovid hits worldwide demand slump: report
Pfizer's COVID-19 antiviral Paxlovid hits worldwide demand slump: report zbecker Tue, 04/19/2022 - 09:02
After rivals’ FDA rebuffs, GSK targets class-first oral approval in chronic kidney disease anemia
After rivals' FDA rebuffs, GSK targets class-first oral approval in chronic kidney disease anemia fkansteiner Tue, 04/19/2022 - 09:02
Asahi Kasei scoops up CDMO Bionova, bolstering its antibody manufacturing capabilities
Asahi Kasei scoops up CDMO Bionova, bolstering its antibody manufacturing capabilities jkeenan Tue, 04/19/2022 - 08:43
Galderma’s ‘Rosacea Space’ provides creative outlet for patients to share their experiences through art, poetry, photography
Galderma's 'Rosacea Space' provides creative outlet for patients to share their experiences through art, poetry, photography nmissakian Tue, 04/19/2022 - 08:42
Pharmas risk losing doctors to digital fatigue in the post-COVID-19 world if they don’t get their email strategy right
Pharmas risk losing doctors to digital fatigue in the post-COVID-19 world if they don't get their email strategy right badams Tue, 04/19/2022 - 08:34
For Incyte’s eczema cream Opzelura, consumer complaint reveals ongoing quality woes, replacement backlog
For Incyte's eczema cream Opzelura, consumer complaint reveals ongoing quality woes, replacement backlog aliu Tue, 04/19/2022 - 07:34
J&J taps tiny Bioasis for tech to cross blood-brain barrier
J&J taps tiny Bioasis for tech to cross blood-brain barrier ntaylor Tue, 04/19/2022 - 05:23
Surf’s up: Startup stoked as Chris Garabedian fund funnels cash into ultra-rapid insulin program
Surf's up: Startup stoked as Chris Garabedian fund funnels cash into ultra-rapid insulin program ntaylor Tue, 04/19/2022 - 05:14
Scientists Question Data Behind an Experimental Alzheimer’s Drug
Studies linked to Cassava Sciences, once a stock market favorite, have been retracted or challenged by medical journals.
Gilead, after setbacks, aims to pull a third of its revenue from oncology business by 2030
Gilead, after setbacks, aims to pull a third of its revenue from oncology business by 2030 kdunleavy Mon, 04/18/2022 - 15:18
Johnson & Johnson inks $99M opioid settlement with West Virginia: report
Johnson & Johnson inks $99M opioid settlement with West Virginia: report zbecker Mon, 04/18/2022 - 14:35
Oft-chided Lupin dinged by FDA at Indian pharmaceutical ingredients plant
Oft-chided Lupin dinged by FDA at Indian pharmaceutical ingredients plant fkansteiner Mon, 04/18/2022 - 13:45
Biden administration official says Americans over 60 should get second COVID booster
Biden administration official says Americans over 60 should get second COVID booster zbecker Mon, 04/18/2022 - 11:21
BeiGene nabs another PD-1 approval in China. Can partner Novartis carry the success to US and Europe?
BeiGene nabs another PD-1 approval in China. Can partner Novartis carry the success to US and Europe? kdunleavy Mon, 04/18/2022 - 11:09